glp 1 with cv benefit Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy SGLT2 inhibitors and finerenone: a narrative review and perspectives | Cardiovascular Diabetology Comprehensive Overview of GLP-1 RAs

This leads to one of two outcomes: programmed cell death (apoptosis) or a state of irreversible growth arrest known as cellular senescence

10.1016/s0278-6915(01)00104-1 152 LeeY

Your GP or pharmacist will review this with you

22 The current proof-of-concept study was designed to evaluate whether (in)GSH is capable of augmenting CNS GSH concentrations, as measured by 1 H-MRS

One-year longitudinal association between changes in dietary choline or betaine intake and cardiometabolic variables in the PREvencion con DIeta MEDiterranea-Plus (PREDIMED-Plus) trial

#obesity #glp1 #healthcareinnovation #healthcaredata Jonathan Rossmans Post Fun fact from a data deep dive that I helped work on: Medicaid spending on GLP-1s has grown exponentially over the past five years with 36 states now covering at least one of the FDA-approved GLP-1s for obesity (Wegovy, Zepbound, or Saxenda) Why